DBV Technologies S.A. (NASDAQ:DBVT) Given Average Rating of … – MarketBeat
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
DBV Technologies S.A. (NASDAQ:DBVT – Get Rating) has been given an average recommendation of “Hold” by the six analysts that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $7.00.
A number of equities research analysts have commented on the company. The Goldman Sachs Group cut DBV Technologies from a “neutral” rating to a “sell” rating in a report on Friday, December 16th. StockNews.com initiated coverage on DBV Technologies in a research report on Saturday, December 24th. They set a “sell” rating for the company.
DBV Technologies Stock Performance
DBVT opened at $1.53 on Friday. The business’s fifty day moving average is $1.41 and its two-hundred day moving average is $1.94. The company has a market cap of $287.72 million, a price-to-earnings ratio of -2.78 and a beta of 1.39. DBV Technologies has a one year low of $1.08 and a one year high of $3.43.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of DBVT. BNP Paribas Arbitrage SNC boosted its holdings in shares of DBV Technologies by 203.3% in the 3rd quarter. BNP Paribas Arbitrage SNC now owns 57,899 shares of the company’s stock valued at $102,000 after purchasing an additional 38,812 shares during the last quarter. Two Sigma Investments LP increased its position in shares of DBV Technologies by 80.9% in the third quarter. Two Sigma Investments LP now owns 35,920 shares of the company’s stock worth $64,000 after acquiring an additional 16,066 shares in the last quarter. Commonwealth Equity Services LLC purchased a new position in shares of DBV Technologies in the 3rd quarter valued at $26,000. Vivo Capital LLC acquired a new position in shares of DBV Technologies during the 3rd quarter valued at $4,795,000. Finally, RA Capital Management L.P. acquired a new stake in DBV Technologies in the 3rd quarter valued at $6,593,000. Institutional investors and hedge funds own 18.37% of the company’s stock.
DBV Technologies Company Profile
(Get Rating)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults.
Read More
- Get a free copy of the StockNews.com research report on DBV Technologies (DBVT)
- MarketBeat: Week in Review 12/26 – 12/30
- The Dogs Of Tech: It’s Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Should You Warm up to Generac Stock for the Winter?
- Is Kintara Therapeutics A Hidden Gem?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider DBV Technologies, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and DBV Technologies wasn’t on the list.
While DBV Technologies currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we’ll send you MarketBeat’s list of the 10 best stocks to own in 2023 and why they should be in your portfolio.
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by entering your email address below.
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
As Featured By:
326 E 8th St #105, Sioux Falls, SD 57103
contact@marketbeat.com
(844) 978-6257
© American Consumer News, LLC dba MarketBeat® 2010-2023. All rights reserved.
© 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.